HENRY A. WAXMAN, CALIFORNIA

JOHN D. DINGELL, MICHIGAN CHAIRMAN EMERITUS EDWARD J. MARKEY, MASSACHUSETTS RICK BOUCHER, VIRGINIA FRANK PALLONE, JR., NEW JERSEY BART GORDON, TENNESSEE BOBBY L. RUSH, ILLINOIS ANNA G. ESHOO, CALIFORNIA BART STUPAK, MICHIGAN ELIOT L. ENGEL, NEW YORK GENE GREEN, TEXAS DIANA DEGETTE, COLORADO VICE CHAIRMAN LOIS CAPPS, CALIFORNIA LOIS CAPPS, CALIFORNIA
MIKE DOYLE, PENNSYLVANIA
JANE HARMAN, CALIFORNIA
JAN SCHAKOWSKY, ILLINOIS
CHARLES A. GONZALEZ, TEXAS
JAY INSLEE, WASHINGTON
TAMMY BALDWIN, WISCONSIN
MIKE ROSS, ARKANSAS
ANIMANNA D. WIENEED, NEW YOR ANTHONY D. WEINER, NEW YORK JIM MATHESON, UTAH G.K. BUTTERFIELD, NORTH CAROLINA CHARLIE MELANCON, LOUISIANA JOHN BARROW, GEORGIA BARON P. HILL, INDIANA DORIS O. MATSUI, CALIFORNIA DONNA CHRISTENSEN, VIRGIN ISLANDS KATHY CASTOR, FLORIDA JOHN SARBANES, MARYLAND CHRISTOPHER MURPHY, CONNECTICUT ZACHARY T. SPACE, OHIO JERRY MCNERNEY, CALIFORNIA BETTY SUTTON, OHIO BRUCE BRALEY, IOWA PETER WELCH, VERMONT

ONE HUNDRED ELEVENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE 2125 RAYBURN HOUSE OFFICE BUILDING

> MAJORITY (202) 225-2927 FACSIMILE (202) 225–2525 MINORITY (202) 225–3641 energycommerce.house.gov

WASHINGTON, DC 20515-6115

October 13, 2010

Mr. Gene L. Dodaro Acting Comptroller General U.S. Government Accountability Office 441 G Street, N.W.

Washington, D.C. 20548

Dear Mr. Dodaro:

I request that the Government Accountability Office (GAO) assess the policies and procedures used by the Agency for Healthcare Research and Quality (AHRQ) in conducting research on comparative effectiveness. AHRQ has the power to gather evidence on the benefits or harms of treatment options, and to provide results on what AHRQ believes is the most effective manner of treatment. Moreover, under the Patient Protection and Affordable Care Act (PPACA), AHRQ will play an integral role in public health policies and will affect the future reimbursement rates for Medicare and Medicaid.

I believe it is important to review the procedures AHRQ uses in researching and recommending the most effective methods of medical treatment. Because the PPACA gives AHRQ vast new responsibilities, I also believe that it is important to analyze how AHRQ has dealt with large legislative implementation in the past and how it plans to address the PPACA.

I would like GAO to analyze the following:

- In February 2009, Congress passed the American Recovery and Reinvestment Act (ARRA), which allocated a substantial amount of money for comparative effectiveness research. I would like the GAO to examine the use of these stimulus funds by AHRO. In particular, I would like information on the topics researched and the recommendations that have been or will be made because of research conducted with these funds.
- The PPACA contains a number of references to AHRQ and comparative effectiveness research. Specifically, Sections 6301 and 937 cover comparative effectiveness research and AHRQ's role in the dissemination of that research. I would like GAO to examine the new responsibilities the law creates for AHRO, particularly whether AHRO will be able to handle these new responsibilities, and what new information or studies are required by the PPACA.

JOE BARTON, TEXAS
RANKING MEMBER

ROY BLUNT, MISSOURI DEPUTY RANKING MEMBER RALPH M. HALL, TEXAS FRED UPTON, MICHIGAN CLIFF STEARNS, FLORIDA ED WHITFIELD, KENTUCKY JOHN SHIMKUS, ILLINOIS JOHN B. SHADEGG, ARIZONA STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA MARY BONO MACK, CALIFORNIA LEE TERRY, NEBRASKA MIKE ROGERS, MICHIGAN MIKE ROGERS, MICHIGAN
SUE WILKINS MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE PHIL GINGREY, GEORGIA STEVE SCALISE, LOUISIANA PARKER GRIFFITH, ALABAMA ROBERT E. LATTA, OHIO

3. As the above two inquiries demonstrate, recent legislation has increased the size of the role of AHRQ. I would, therefore, like GAO to provide an extensive examination of AHRQ's decision-making process and the method by which it conducts comparative effectiveness research. Specifically, I would like GAO to identify the methodologies and criteria used by AHRQ for topic selection, studies, stakeholder input, and dissemination to the public.

We look forward to discussing this proposed study with you soon. Please contact Republican Committee staff at (202) 225-3641 if you have any questions or concerns about these requests.

Sincerely,

Joe Barton

Ranking Member

cc: The Honorable Henry A. Waxman, Chairman